These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 31779670)

  • 41. Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease.
    Chatterjee P; Zetterberg H; Goozee K; Lim CK; Jacobs KR; Ashton NJ; Hye A; Pedrini S; Sohrabi HR; Shah T; Asih PR; Dave P; Shen K; Taddei K; Lovejoy DB; Guillemin GJ; Blennow K; Martins RN
    J Neuroinflammation; 2019 Oct; 16(1):186. PubMed ID: 31601232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of rs2062323 in the TREM1 gene with Alzheimer's disease and cerebrospinal fluid-soluble TREM2.
    Wang ZT; Fu Y; Chen SD; Huang YY; Ma YH; Wang YJ; Tan L; Yu JT
    CNS Neurosci Ther; 2023 Jun; 29(6):1657-1666. PubMed ID: 36815315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection.
    Gisslén M; Heslegrave A; Veleva E; Yilmaz A; Andersson LM; Hagberg L; Spudich S; Fuchs D; Price RW; Zetterberg H
    Neurol Neuroimmunol Neuroinflamm; 2019 Jan; 6(1):e512. PubMed ID: 30568991
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Higher Peripheral TREM2 mRNA Levels Relate to Cognitive Deficits and Hippocampal Atrophy in Alzheimer's Disease and Amnestic Mild Cognitive Impairment.
    Tan YJ; Ng ASL; Vipin A; Lim JKW; Chander RJ; Ji F; Qiu Y; Ting SKS; Hameed S; Lee TS; Zeng L; Kandiah N; Zhou J
    J Alzheimers Dis; 2017; 58(2):413-423. PubMed ID: 28453482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
    Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study.
    Quiroz YT; Zetterberg H; Reiman EM; Chen Y; Su Y; Fox-Fuller JT; Garcia G; Villegas A; Sepulveda-Falla D; Villada M; Arboleda-Velasquez JF; Guzmán-Vélez E; Vila-Castelar C; Gordon BA; Schultz SA; Protas HD; Ghisays V; Giraldo M; Tirado V; Baena A; Munoz C; Rios-Romenets S; Tariot PN; Blennow K; Lopera F
    Lancet Neurol; 2020 Jun; 19(6):513-521. PubMed ID: 32470423
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genome-Wide Association Studies for Cerebrospinal Fluid Soluble TREM2 in Alzheimer's Disease.
    Liu C; Yu J
    Front Aging Neurosci; 2019; 11():297. PubMed ID: 31708768
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
    Wagemann O; Liu H; Wang G; Shi X; Bittner T; Scelsi MA; Farlow MR; Clifford DB; Supnet-Bell C; Santacruz AM; Aschenbrenner AJ; Hassenstab JJ; Benzinger TLS; Gordon BA; Coalier KA; Cruchaga C; Ibanez L; Perrin RJ; Xiong C; Li Y; Morris JC; Lah JJ; Berman SB; Roberson ED; van Dyck CH; Galasko D; Gauthier S; Hsiung GR; Brooks WS; Pariente J; Mummery CJ; Day GS; Ringman JM; Mendez PC; St George-Hyslop P; Fox NC; Suzuki K; Okhravi HR; Chhatwal J; Levin J; Jucker M; Sims JR; Holdridge KC; Proctor NK; Yaari R; Andersen SW; Mancini M; Llibre-Guerra J; Bateman RJ; McDade E;
    JAMA Neurol; 2024 Jun; 81(6):582-593. PubMed ID: 38683602
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum Soluble Triggering Receptor Expressed on Myeloid Cells 2 as a Biomarker for Incident Dementia: The Hisayama Study.
    Ohara T; Hata J; Tanaka M; Honda T; Yamakage H; Yoshida D; Inoue T; Hirakawa Y; Kusakabe T; Shibata M; Teraoka T; Kitazono T; Kanba S; Satoh-Asahara N; Ninomiya T
    Ann Neurol; 2019 Jan; 85(1):47-58. PubMed ID: 30485483
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased CSF Soluble TREM2 Concentration in Patients With Neurosyphilis.
    Li W; Chang H; Wu W; Xu D; Jiang M; Gao J; Huang Y; Xu Y; Yin L; Zhang X
    Front Neurol; 2020; 11():62. PubMed ID: 32117023
    [No Abstract]   [Full Text] [Related]  

  • 51. Peripheral TREM2 mRNA levels in early and late-onset Alzheimer disease's patients.
    Guven G; Bilgic B; Samanci B; Gurvit H; Hanagasi H; Donmez C; Aslan R; Lohmann E; Erginel-Unaltuna N
    Mol Biol Rep; 2020 Aug; 47(8):5903-5909. PubMed ID: 32681391
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elevated sTREM2 and NFL levels in patients with sepsis associated encephalopathy.
    Orhun G; Esen F; Yilmaz V; Ulusoy C; Şanlı E; Yıldırım E; Gürvit H; Ergin Özcan P; Sencer S; Bebek N; Tüzün E
    Int J Neurosci; 2023 Mar; 133(3):327-333. PubMed ID: 33851572
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association study of serum soluble TREM2 with vascular dementia in Chinese Han population.
    Wang Q; Xu Y; Qi C; Liu A; Zhao Y
    Int J Neurosci; 2020 Jul; 130(7):708-712. PubMed ID: 31847649
    [No Abstract]   [Full Text] [Related]  

  • 54. Plasma neurofilament light chain levels in Alzheimer's disease.
    Zhou W; Zhang J; Ye F; Xu G; Su H; Su Y; Zhang X;
    Neurosci Lett; 2017 May; 650():60-64. PubMed ID: 28428015
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does Soluble TREM2 Protect Against Alzheimer's Disease?
    Brown GC; St George-Hyslop P
    Front Aging Neurosci; 2021; 13():834697. PubMed ID: 35153729
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer's disease brains.
    Ma L; Allen M; Sakae N; Ertekin-Taner N; Graff-Radford NR; Dickson DW; Younkin SG; Sevlever D
    Mol Neurodegener; 2016 Nov; 11(1):72. PubMed ID: 27887626
    [TBL] [Abstract][Full Text] [Related]  

  • 57. R47H Variant of TREM2 Associated With Alzheimer Disease in a Large Late-Onset Family: Clinical, Genetic, and Neuropathological Study.
    Korvatska O; Leverenz JB; Jayadev S; McMillan P; Kurtz I; Guo X; Rumbaugh M; Matsushita M; Girirajan S; Dorschner MO; Kiianitsa K; Yu CE; Brkanac Z; Garden GA; Raskind WH; Bird TD
    JAMA Neurol; 2015 Aug; 72(8):920-7. PubMed ID: 26076170
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TREM2 Expression and Amyloid-Beta Phagocytosis in Alzheimer's Disease.
    La Rosa F; Agostini S; Piancone F; Marventano I; Hernis A; Fenoglio C; Galimberti D; Scarpini E; Saresella M; Clerici M
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239970
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Wild-type sTREM2 blocks Aβ aggregation and neurotoxicity, but the Alzheimer's R47H mutant increases Aβ aggregation.
    Vilalta A; Zhou Y; Sevalle J; Griffin JK; Satoh K; Allendorf DH; De S; Puigdellívol M; Bruzas A; Burguillos MA; Dodd RB; Chen F; Zhang Y; Flagmeier P; Needham LM; Enomoto M; Qamar S; Henderson J; Walter J; Fraser PE; Klenerman D; Lee SF; St George-Hyslop P; Brown GC
    J Biol Chem; 2021; 296():100631. PubMed ID: 33823153
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of soluble TREM2 with Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis.
    Wang R; Zhan Y; Zhu W; Yang Q; Pei J
    Front Aging Neurosci; 2024; 16():1407980. PubMed ID: 38841103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.